Short-course radiation plus chemo and a PD-1 antibody
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies a shorter course of radiation for rectal cancer, followed by chemotherapy and an immune treatment called a PD-1 inhibitor. It aims to improve treatment outcomes for people with locally advanced rectal cancer that has not spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal adenocarcinoma confirmed by biopsy (a tissue test).
- Your tumor is within 10 cm of the anus, based on exam/scans.
- Your cancer is “locally advanced” (not spread to distant organs), confirmed by pelvic MRI or endoscopic ultrasound.
- You are well enough for treatment (ECOG 0–1) and your blood, kidney, and liver test results are within required ranges.
- You have never had radiation to the pelvis before, and you have not started any cancer treatment right after diagnosis.
- You can not have had prior PD-1/PD-L1 or CTLA-4 immune therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that uses a short course of radiation to the lymph nodes-sparing area, followed by chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of mid or low rectal cancer (pMMR/MSS). The goal is to see if this approach can shrink the tumor and improve outcomes without needing extensive surgery.
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests a shorter course of radiation that avoids draining lymph nodes, followed by an immunotherapy drug (PD-1 inhibitor), for people with stage II or III rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink tumors while keeping lymph nodes intact.
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
Hear when a new Rectal Neoplasms Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.